Loading
Latest filing published 06 Mar 2026 for SynAct Pharma AB, €4,510. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
No signal scores available.
One trade, one date: on 6 March 2026, Thomas Boesen disclosed an open-market purchase of €4,510 in SynAct Pharma AB. No broader history exists yet. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration